TransCode Therapeutics, Inc.
RNAZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $24 | $23 | $5,649 | $13,842 |
| - Cash | $6 | $3 | $5 | $21 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $18 | $21 | $5,644 | $13,821 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$16 | -$18 | -$17 | -$7 |
| % Margin | – | – | – | – |
| Net Income | -$17 | -$19 | -$18 | -$7 |
| % Margin | – | – | – | – |
| EPS Diluted | -47.14 | -3,453.53 | -1,080 | -648 |
| % Growth | 98.6% | -219.8% | -66.7% | – |
| Operating Cash Flow | -$13 | -$18 | -$16 | -$5 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$13 | -$18 | -$16 | -$6 |